Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Cancer Cell

Volumn 28, Issue 3, 2015, Pages 384-398

  Peng, Sheng Bin ^a   Henry, James R ^a   Kaufman, Michael D ^b   Lu, Wei Ping ^b   Smith, Bryan D ^b   Vogeti, Subha ^b   Rutkoski, Thomas J ^b   Wise, Scott ^b   Chun, Lawrence ^c   Zhang, Youyan ^a   Van Horn, Robert D ^a   Yin, Tinggui ^a   Zhang, Xiaoyi ^a   Yadav, Vipin ^a   Chen, Shih Hsun ^a   Gong, Xueqian ^a   Ma, Xiwen ^a   Webster, Yue ^a   Buchanan, Sean ^a   Mochalkin, Igor ^a   Huber, Lysiane ^a   Kays, Lisa ^a   Donoho, Gregory P ^a   Walgren, Jennie ^a   McCann, Denis ^a   Patel, Phenil ^a   Conti, Ilaria ^a   Plowman, Gregory D ^a   Starling, James J ^a   Flynn, Daniel L ^b   more..

^a ELI LILLY AND COMPANY   (United States)

^b Deciphera Pharmaceuticals   (United States)

^c Emerald BioStructures   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,3 DIMETHYLBUTYL) 3 (2 FLUORO 4 METHYL 5 (7 METHYL 2 (METHYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 6 YL)PHENYL)UREA; A RAF KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; DABRAFENIB; DIMER; HOMODIMER; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAF PROTEIN; SELUMETINIB; TRAMETINIB; TUBULIN; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; LY3009120; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BIOCHEMICAL ANALYSIS; BRAF GENE; COLORECTAL TUMOR; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MUTATION; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIMERIZATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASMS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PYRIMIDINES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84942323259     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.08.002     Document Type: Article

References (49)

1. Baljuls A., Mahr R., Schwarzenau I., Muller T., Polzien L., Hekman M., Rapp U.R. Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. J. Biol. Chem. 2011, 286:16491-16503.
2. Blasco R.B., Francoz S., Santamaria D., Canamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
3. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
4. Bollag G., Tsai J., Zhang J., Zhang C., Ibrahim P., Nolop K., Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 2012, 11:873-886.
5. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
6. Cox A.D., Fesik S.W., Kimmelman A.C., Luo J., Der C.J. Drugging the undruggable RAS: Mission possible?. Nat. Rev. Drug Discov. 2014, 13:828-851.
7. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
8. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. USA 1982, 79:3637-3640.
9. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
10. Farrar M.A., Alberol-Ila J., Perlmutter R.M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 1996, 383:178-181.
11. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
12. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367:107-114.
13. Freeman A.K., Ritt D.A., Morrison D.K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 2013, 49:751-758.
14. Girotti M.R., Lopes F., Preece N., Niculescu-Duvaz D., Zambon A., Davies L., Wittaker S., Saturno G., Viros A., Pedersen M., et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 2015, 27:85-96.
15. Halilovic E., She Q.-B., Ye Q., Pagliarini R., Sellers W.R., Solit D.B., Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 2010, 70:6804-6814.
16. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
17. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
18. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
19. Henry J.R., Kaufman M.D., Peng S.B., Ahn Y.M., Caldwell T.M., Vogeti L., Telikepalli H., Lu W.P., Hood M.M., Rutkoski T.J., et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. J. Med. Chem. 2015, 58:4165-4173.
20. Holderfield M., Merritt H., Chan J., Wallroth M., Tandeske L., Zhai H., Tellew J., Hardy S., Hekmat-Nejad M., Stuart D.D., et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 2013, 23:594-602.
21. Hu J., Stites E.C., Yu H., Germino E.A., Meharena H.S., Stork P.J.S., Kornev A.P., Taylor S.S., Shaw A.S. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 2013, 154:1036-1046.
22. Karreth F.A., Frese K.K., DeNicola G.M., Baccarini M., Tuveson D.A. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011, 1:128-136.
23. King A.J., Arnone M.R., Bleam M.R., Moss K.G., Yang J., Fedorowicz K.E., Smitheman K.N., Erhardt J.A., Hughes-Earle A., Kane-Carson L.S., et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS ONE 2013, 8:e67583.
24. Lamba S., Russo M., Sun C., Lazzari L., Cancelliere C., Grernrum W., Lieftink C., Bernards R., Di Nicolantonio F., Bardelli A. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 2014, 8:1475-1483.
25. Lito P., Saborowski A., Yue J., Solomon M., Joseph E., Gadal S., Saborowski M., Kastenhuber E., Fellmann C., Ohara K., et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 2014, 25:697-710.
26. Luo Z., Tzivion G., Belshaw P.J., Vavvas D., Marshall M., Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996, 383:181-185.
27. Nakamura A., Arita T., Tsuchiya S., Donelan J., Chouitar J., Carideo E., Galvin K., Okaniwa M., Ishikawa T., Yoshida S. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013, 73:7043-7055.
28. Okaniwa M., Hirose M., Arita T., Yabuki M., Nakamura A., Takagi T., Kawamoto T., Uchiyama N., Sumita A., Tsutsumi S., et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J. Med. Chem. 2013, 56:6478-6494.
29. Ozawa T., Kaihara A., Sato M., Tachihara K., Umezawa Y. Split luciferase as an optical probe for detecting protein-protein interactions in mammalian cells based on protein splicing. Anal. Chem. 2001, 73:2516-2521.
30. Packer L., Marais R. Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Cancer Cell 2011, 19:435-437.
31. Patricelli M.P., Nomanbhoy T.K., Wu J., Brown H., Zhou D., Zhang J., Jagannathan S., Aban A., Okerberg E., Herring C., et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 2011, 18:699-710.
32. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
33. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
34. Pratilas C.A., Hanrahan A.J., Halilovic E., Persaud Y., Soh J., Chitale D., Shigematsu H., Yamamoto H., Sawai A., Janakiraman M., et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008, 68:9375-9383.
35. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
36. Rajakulendran T., Sahmi M., Lefrancois M., Sicheri F., Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545.
37. Roring M., Herr R., Fiala G.J., Heilmann K., Braun S., Eisenhardt A.E., Halbach S., Capper D., von Deimling A., Schamel W.W., et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 2012, 31:2629-2647.
38. Sanchez-Laorden B., Viros A., Girotti M.R., Pedersen M., Saturno G., Zambon A., Niculescu-Duvaz D., Turajlic S., Hayes A., Gore M., et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 2014, 7:ra30.
39. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
40. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
41. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958, 26:24-36.
42. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
43. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
44. Wang X., Kim J. Conformation-specific effects of Raf kinase inhibitors. J. Med. Chem. 2012, 55:7332-7341.
45. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 2001, 61:3595-3598.
46. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.-M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
47. Yadav V., Zhang X., Liu J., Estrem S., Li S., Gong X.-Q., Buchanan S., Henry J.R., Starling J.J., Peng S.-B. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 2012, 287:28087-28098.
48. Yadav V., Burke T.F., Huber L., Van Horn R.D., Zhang Y., Buchanan S.G., Chan E.M., Starling J.J., Beckmann R.P., Peng S.-B. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol. Cancer Ther. 2014, 13:2253-2263.
49. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J.F., et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010, 70:5518-5527.